New pain drug HRS-2129 tested in healthy adults
NCT ID NCT06742840
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed Phase 1 study tested the safety and tolerability of HRS-2129, a new drug for pain, in 23 healthy adults aged 18 to 55. Researchers measured side effects and how the body processes the drug, along with pain responses to cold and heat. Because it was only in healthy volunteers, it does not yet show if the drug helps people with chronic pain.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS-2129
- What this could lead to
- If successful, this could point toward a new pain treatment option.
- What could go wrong
- This is an early Phase 1 study in healthy people, not patients. It only tests safety and basic pain response, so it may not work for real pain conditions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Third Xiangya Hospital of Central South University
Changsha, Hunan, 410013, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Tape to tame Post-Surgery face swelling?
- Electric pulses on the wrist may tame colonoscopy pain
- Virtual reality may distract patients from pain and fear during anesthesia
- Could a gentle yoga practice turn down the Body's pain and inflammation?
- Can a 5-Pill opioid prescription match a 30-Pill one after hip surgery?
- Parkinson's pain: could a new Add-On drug bring relief?